Try our beta test site
IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more...

Effect of Food and Antacid on BIIB021 With Advanced Solid Tumors

This study has been completed.
Information provided by:
Biogen Identifier:
First received: November 18, 2009
Last updated: September 12, 2013
Last verified: January 2011
This study is designed to assess the effect of food and antacid use on the pharmacokinetic properties of BIIB021.

Condition Intervention Phase
Advanced Solid Tumors
Drug: BIIB021 and Food
Drug: BIIB0121 and Antacid
Phase 1

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Crossover Assignment
Masking: Open Label
Primary Purpose: Treatment
Official Title: An Assessment of the Effect of Food and Antacid on BIIB021 Pharmacokinetics in Subjects With Advanced Solid Tumors.

Further study details as provided by Biogen:

Primary Outcome Measures:
  • The primary objective of the study is to assess the pharmacokinetics of BIIB021 taken under fed conditions compared to BIIB021 taken under fasting conditions in subjects with advanced solid tumors. [ Time Frame: Cycle 1, Day 3 ]

Secondary Outcome Measures:
  • To assess the pharmacokinetics of BIIB021 taken with an antacid (ranitidine) compared to BIIB021 taken with no antacid, both under fasting conditions [ Time Frame: Cycle 1, Day 8 and Day 10 ]
  • To evaluate the safety and tolerability of BIIB021 [ Time Frame: 6 months ]
  • To evaluate the antitumor activity of BIIB021 [ Time Frame: 6 months ]
  • To evaluate the effect of BIIB021 on pharmacodynamic biomarkers. [ Time Frame: 6 months ]

Enrollment: 20
Study Start Date: November 2009
Study Completion Date: January 2011
Primary Completion Date: August 2010 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: BIIB021 and Food
The food phase will assess the effect of a high fat meal on the pharmacokinetics of BIIB021.
Drug: BIIB021 and Food
Assessing the effect of food use on BIIB021
Experimental: BIIB021 and Antacid
Antacid phase will assess the effect of an antacid on the pharmacokinetics of BIIB021.
Drug: BIIB0121 and Antacid
Assessing the effect of antacid use on BIIB021

Detailed Description:
This study has 2 phases (the Food Phase and the Antacid Phase), each consisting of a 2-period, 2-sequence, 2-treatment crossover design. The Food Phase will assess the effect of a high fat meal on the pharmacokinetics of 100 mg BIIB021, and the Antacid Phase will assess the effect of an antacid (ranitidine) on the pharmacokinetics of 450 mg BIIB021 in the same subjects. Ranitidine 150 mg will be taken the evening before and the morning of the antacid dosing day.

Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Subjects with histologically or cytologically confirmed solid tumors who have failed or are not candidates for standard therapies or for whom no approved therapy is available.
  • Eastern Cooperative Oncology Group (ECOG) performance status of greater or equal to 2.
  • Medically able to tolerate a high fat meal and to fast as per protocol.
  • Expected survival time of at least 3 months in the opinion of the Investigator.
  • Ability to take ranitidine as per protocol.
  • Must be able to swallow and retain oral medication.
  • Lab values consistent with adequate renal, hepatic, and bone marrow functions.
  • Electrocardiogram (ECG) with QTc of ≤450 msec for men or ≤470 msec for women and no clinically significant findings.

Exclusion Criteria:

  • Pregnant (positive pregnancy test) or nursing women.
  • Previous treatment with an Hsp90 inhibitor.
  • Use of antacids within 7 days of Study Day 1.
  • Prior antitumor therapies, including prior experimental agents or approved antitumor therapies within 28 days of the first dose of BIIB021.
  • Major surgery or radiation within 28 days of the first dose of BIIB021.
  • Uncontrolled, severe medical illness, which in the opinion of the Investigator and/or Sponsor could compromise protocol objectives.
  • History of gastrectomy or major surgery to small intestine.
  • History of exocrine pancreatic insufficiency.
  • Chronic diarrhea (excess of 2 to 3 stools/day above normal frequency).
  • Active bacterial or viral infection requiring concurrent treatment.
  • History of hepatitis B or C or human immunodeficiency virus.
  • History of central nervous system metastasis.
  • Any thrombotic event occurred <3 months prior to Day 1.
  • Conditions that may predispose subjects to seizures: History of seizure, previous significant head trauma
  • Drug or alcohol abuse.
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT01017198

United States, Arizona
Reseach Facility
Scottsdale, Arizona, United States
United States, California
Reseach Facility
Encinitas, California, United States
United States, Texas
Reseach Facility
San Antonio, Texas, United States
Sponsors and Collaborators
  More Information

Responsible Party: Biogen Idec MD, Biogen Idec Identifier: NCT01017198     History of Changes
Other Study ID Numbers: 120ST104
Study First Received: November 18, 2009
Last Updated: September 12, 2013

Additional relevant MeSH terms:
Anti-Ulcer Agents
Molecular Mechanisms of Pharmacological Action
Gastrointestinal Agents processed this record on May 22, 2017